CONFERENCE UPDATE: ASCO 2022

PALOMA-2: OS of 1L treatment with palbociclib + letrozole vs. placebo + letrozole in women with ER+, HER2- ABC

OBSTETRICS & GYNECOLOGY ONCOLOGY
29 Jul 2022

Glossary: ABC: Advanced breast cancer; AEs: Adverse events; BC: Breast cancer; CDK4/6i: Cyclin-dependent kinase 4/6 inhibitor; CI: Confidence interval; DFI: Disease-free survival; ECOG: Eastern Cooperation Oncology Group; ER+: Estrogen receptor-positive; HER2-: Human epidermal growth factor receptor 2-negative; HR: Hazard ratio; HR+: Hormone receptor-positive; OS: Overall survival; PFS: Progression-free survival; PS: Performance status; QD: Once daily; TTC: Time-to-chemotherapy

References
  1. Finn RS et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growthfactor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2. Presented at the 2022 ASCO Annual Meeting; June 3-7, 2022
PALOMA-2
PALBOCICLIB
LETROZOLE
HER2- ABC
ER-POSITIVE
HER2-NEGATIVE ADVANCED BREAST CANCER